News

Get to know what's happening behind the scenes.

Learn more

Featured

Blog

Read the latest on our blog. Let's Talk Innovation.

Social

Stay connected with us on social media.

twitter_logo_20px.jpg @JNJinnovation

Events

Press Releases

Read our latest news.

  • Global Corporate Venturing Rising Stars Awards 2017: #19 Renee Ryan

  • Octimet Oncology joins the JLINX Community

    Beerse, Belgium
    January 19, 2017

    OCTIMET Oncology NV (OCTIMET), has secured EUR 11.3 million in a Series A investment round, enabling the company to accelerate the development of a clinically de-risked MET kinase inhibitor, as single agent or in combination with standard of care and targeted agents for the treatment of solid cancers.

    OCTIMET was founded in 2016 by Timothy Perera PhD, Ann Meulemans PhD, Paolo Comoglio, MD, PhD and Philip Owen FCA. Headed by Dr. Timothy Perera, OCTIMET has licensed highly selective MET kinase inhibitors from Janssen Pharmaceutica NV and will advance the development of these molecules by employing innovative patient selection and pharmacodynamic biomarker-based approaches, as well as an innovative clinical development strategy, to provide differentiation both within the current treatment paradigms and from competitor agents. 

  • Johnson & Johnson Innovation, New York State, and New York Genome Center Collaborate to Launch JLABS in New York City

    NEW YORK CITY, Jan. 9, 2017 — Johnson & Johnson Innovation LLC, New York State, and the New York Genome Center today announced a collaboration to launch a new JLABS in New York City. Called JLABS @ NYC, the 30,000-square foot facility will be located at the New York Genome Center (NYGC) in Soho and will open in 2018. The project is receiving $17 million in New York State funding.  The site will be open to biotech, pharmaceutical, medical device and consumer health companies. A Quick Fire Challenge seeking companies working in these areas, particularly startups working on cross-sector solutions to prevent intercept or cure diseases, will be launched by Johnson & Johnson Innovation, with the winner(s) eligible for one year of residency at JLABS @ NYC.

Pages

Accelerators

Close
Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
mail@www.neomed.ca
www.neomed.ca
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.